Anifrolumab, an Anti-Interferon-Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus -

Anifrolumab, an Anti-Interferon-Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus
Information type: Randomised controlled trials
Source: Arthritis & Rheumatology
Specialities: Skin disorders
Summary
In this RCT (n=305), primary endpoint (percent of patients achieving an SLE Responder Index response at week 24 with sustained reduction of corticosteroids) was met by more anifrolumab-treated patients than placebo -17.6% placebo, 34.3% and 28.8% for anifrolumab 300mg and 1000mg.
UKMi comment
Anifrolumab is currently in phase III development for systemic lupus erythematosus. It is a fully human monoclonal antibody that binds to subunit 1 of the Type I IFN receptor, inhibiting the activity of all Type I IFNs including IFN-α, IFN-β and IFN-ω.
Related links: